TO BE PUBLISHED March 2022
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
This conference will examine what is needed to improve diagnostic speed and outcomes.
It will also be an opportunity to discuss the future outlook for medical device regulation in the wake of Brexit, with the MHRA having consulted on a more transparent and flexible approach.
Further sessions look at supporting continued research and innovation, with the Government launching strategic and funding plans t, including investment in modernising diagnostics as part of wider efforts to address waiting lists.
Additional areas for discussion include:
- industry partnerships
- staff recruitment and retention
- learning from the response to COVID-19
- opportunities for driving efficiencies
We are very pleased to be able to include keynote sessions with:
- Professor Sir Mark Caulfield, Professor of Clinical Pharmacology, Queen Mary University of London; Chief Executive Officer, Barts Life Sciences; and former Chief Scientist, Genomics England
- Dr Sarah Byron, Programme Director, Centre for Health Technology Evaluation, NICE
- Professor Louise Jones, Chair, Genomics and Reproductive Science Specialty Advisory Committee, Royal College of Pathologists; and Professor of Breast Pathology, Barts Cancer Institute
- Stephen Lee, Director, Diagnostics Regulation, Association of British Healthcare Industries
- Professor Michael Messenger, Principal Scientific Advisor for In Vitro Diagnostics, MHRA
- Doris-Ann Williams, Chief Executive, British In Vitro Diagnostics Association
The discussion is bringing together stakeholders with key policy officials who are due to attend from BEIS; the DHSC; the Department of Health, NI; the DIT; the MHRA; Government Office for Science; the OLS; the UKHSA; The Scottish Government; and the Welsh Government - as well as parliamentary pass-holders from both Houses of Parliament.